Organon & -Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know

Company Performance - Organon (OGN) closed at $14.56, down 1.02% from the previous day, underperforming the S&P 500, which fell 0.33% [1] - Over the past month, Organon shares declined by 4.97%, worse than the Medical sector's loss of 3.24% and the S&P 500's loss of 4.03% [1] Upcoming Earnings - Analysts expect Organon to report earnings of$ 0.92 per share, reflecting a year-over-year decline of 24.59% [2] - Revenue is forecasted to be $1.54 billion, indicating a 4.97% decline compared to the same quarter last year [2] Fiscal Year Estimates - For the fiscal year, earnings are projected at$ 3.79 per share and revenue at $6.27 billion, representing declines of 7.79% and 2.14% respectively from the prior year [3] - Recent changes in analyst estimates may indicate the company's near-term business trends and overall health [3] Valuation Metrics - Organon has a Forward P/E ratio of 3.88, significantly lower than the industry average of 16.08 [6] - The PEG ratio for Organon is 1.63, compared to the Medical Services industry's average PEG ratio of 1.46 [6] Industry Ranking - The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 71, placing it in the top 29% of over 250 industries [7] - Strong industry rankings correlate with better stock performance, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]